Aristolone is an aristolane sesquiterpene ketone with a stronger literature footprint than many obscure aroma constituents because a recent study directly tested isolated (-)-aristolone in vascular and hypertensive rodent models. Live sources strongly support identity, naming, and occurrence, while the main mechanism evidence points to vasorelaxant signaling through the PDK1-Akt-eNOS pathway and KATP-channel involvement. Even so, the benefit literature is still preclinical, so AromaForge should describe aristolone as a chemically defined sesquiterpene ketone with early cardiovascular and assay-screening interest rather than a proven human therapeutic.
Chemical identity and composition
PubChem resolves aristolone to CID 165536 with formula C15H22O, InChIKey UGVIZCBJCSXBCJ-JWFUOXDNSA-N, and computed TPSA 17.1. PubChem synonym data also list both Aristol-9-en-8-one and the alternate CAS 25274-27-5, while the local archive and recent pharmacology paper use CAS 6831-17-0. In the Bengali nagarmotha oil profile, aristolone appears at 1.92%, making it a notable minor ketonic sesquiterpene rather than a trace impurity.
Aroma and practical use
- Use the recorded characteristic, woody, herbal, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2022 Phytomedicine study found that isolated (-)-aristolone induced vasorelaxation in thoracic aorta and mesenteric artery preparations and lowered systolic and diastolic blood pressure in spontaneously hypertensive rats.
This is the strongest directly attributable aristolone paper located in this pass and anchors the constituent's preclinical cardiovascular relevance.
This experimental finding does not establish benefit, dose or safety in people using this blend.
The same 2022 study reported that PHT-427 and L-NAME inhibited aristolone-induced vasorelaxation, while glibenclamide reduced the endothelium-denuded response, supporting both PDK1-Akt-eNOS signaling and KATP-channel involvement.
This supports a mechanism-oriented description without exceeding the evidence base.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2018 Planta Medica quality-control study identified (-)-aristolone as one of six fingerprinted constituents in Nardostachys jatamansi and reported that, unlike five of the other isolated compounds tested, it showed no serotonin transporter activity in the assay used.
This is useful negative evidence because it narrows one hypothesized neuropharmacology angle rather than inflating it.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedNo human clinical safety trial or formal fragrance-safety review specific to isolated aristolone was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Because isolated aristolone lowered blood pressure in hypertensive rats, archive copy should avoid implying that it is biologically inert or broadly established as safe at concentrated exposures.
This experimental finding does not establish benefit, dose or safety in people using this blend.
The current benefit literature is preclinical and should not be converted into medical claims about hypertension or cardiovascular disease.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
pdk1_akt_enos_linked_endothelial_vasorelaxation
In endothelial cells and vascular preparations, (-)-aristolone was linked to PDK1 interaction, increased Akt and eNOS phosphorylation, and nitric-oxide-associated vasorelaxation.
This experimental finding does not establish benefit, dose or safety in people using this blend.
katp_channel_involvement_in_endothelium_independent_relaxation
Glibenclamide inhibited aristolone-associated vasorelaxation in endothelium-denuded thoracic aorta, supporting KATP-channel involvement in part of the response.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No human clinical aristolone study was verified in this pass.
- The strongest efficacy-style evidence is one recent cardiovascular preclinical paper and should be treated as early-stage.
- Formal constituent-specific safety review coverage remains sparse compared with more common fragrance ingredients.
- 2026-07-13 re-verification (worker c3): a targeted search for aristolone (CAS 6831-17-0) dermal safety data returned only chemical-supplier identity pages; no authoritative constituent-specific safety data located, dermal_limit_verified remains false.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.